Becton Dickinson's BD Diagnostics gets FDA clearance for its BD ProbeTec

Becton, Dickinson (BDX -1.7%) subsidiary BD Diagnostics says the FDA has approved their BD ProbeTec Trichomonas vaginalis Amplified DNA Assay for use with the BD Viper System with XTR Technology.

The DNA assay is used for the detection of T. vaginalis DNA in endocervical and vaginal samples as well as neat urine specimens to aid in the diagnosis of trichomoniasis.

From other sites
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs